Application of purine 2Y12 receptor antagonist in preparing medicine for diabetic neuropathological injury diseases

A technology of receptor antagonist and neuropathology, applied in nervous system diseases, anti-inflammatory agents, metabolic diseases, etc., can solve problems such as spontaneous pain, disability, and hyperalgesia of distal limbs

Pending Publication Date: 2018-02-02
NANCHANG UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinically, it is more common in patients with poor blood sugar control. It often manifests as spontaneous pain, hyperalgesia, and allodynia (such as burning sensation, ants walking sensation, or acupuncture sensation) in the distal limbs. There are very few treatments for these abnormal sensations. Limitation, leading to permanent disability in severe cases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of purine 2Y12 receptor antagonist in preparing medicine for diabetic neuropathological injury diseases
  • Application of purine 2Y12 receptor antagonist in preparing medicine for diabetic neuropathological injury diseases
  • Application of purine 2Y12 receptor antagonist in preparing medicine for diabetic neuropathological injury diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Oral or injectable purine 2Y12 receptor antagonist preparations suitable for treating diabetic neuropathic pain are prepared by methods known in the art.

Embodiment 2

[0017] Oral or injectable purine 2Y12 receptor antagonist preparations suitable for the treatment of diabetic nerve injury-related diseases are prepared by methods known in the technical field.

Embodiment 3

[0019] The oral or injectable purine 2Y12 receptor antagonist preparation suitable for the treatment of diabetic sensory neuroinflammation-related diseases is prepared by a method known in the technical field.

[0020] In a word, the purine 2Y12 receptor antagonists can be used for oral administration, injection, buccal tablets or other local or systemic dosage forms for the prevention and treatment of the above-mentioned diseases.

[0021] In order to better understand the essence of the present invention, the use of purine 2Y12 receptor antagonists will be demonstrated by the experiments and results of the research on purine 2Y12 receptor antagonists for the treatment of related diseases mediated by purine 2Y12 receptors.

[0022] 1. Materials and methods.

[0023] 1. High-glucose and high-fat cell model creation and grouping.

[0024] According to literature reports and pre-experimental results, in this experiment, glucose concentration of 30 mM and free fatty acid concent...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a purine 2Y12 receptor antagonist in preparing medicine for diabetic neuropathological damage diseases. Experiments verify that the purine 2Y12 receptor antagonist can lower expression of dorsal root ganglion satellite glial cell purine 2Y12 receptor and reduce inflammatory medium release, and prompts that the purine 2Y12 receptor antagonist can inhibit transmission of nociceptive information mediated by the dorsal root ganglion purine 2Y12 receptor and relieve diabetic rat nerve injury and related diseases (including diseases like neuropathic pain), andthe purein 2Y12 receptor antagonist can be applied in preparing drug for treating diabetic neuropathological injury related diseases and neuropathic pain.

Description

technical field [0001] The present invention relates to the invention field of diabetic neuropathic injury diseases and neuropathic pain drugs, and in particular relates to the use of purine 2Y12 (P2Y12) receptor antagonists in the preparation of drugs for reducing neuropathic injury diseases and neuropathic pain caused by diabetic injuries Its mechanism of action involves inhibiting the information transmission of diabetic neuropathic pain mediated by the purine 2Y (P2Y) 12 receptor in the dorsal root ganglion. Background technique [0002] Diabetes Mellitus (DM) is a group of metabolic clinical syndromes. With the development of society and the improvement of people's living standards, the prevalence of diabetes is increasing year by year, and its mortality rate is listed as the fatality rate of diseases in most high-income countries. It ranks fifth or even fourth, becoming the fourth priority disease after cancer, AIDS, and cardiovascular and cerebrovascular diseases. Di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61P3/10A61P25/00A61P29/00
CPCA61K45/00
Inventor 梁尚栋王寿玉刘双梅邹丽芳李桂林高云徐宏赵珊红贾天宇李琳袁辉龙石理冉
Owner NANCHANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap